Long pages
Showing below up to 50 results in range #1 to #50.
- (hist) 32. Cell signalling, receptors and kinases [27,581 bytes]
- (hist) 10. Pharmacokinetics: zero and first order elimination kinetics, elimination half-life, volume of distribution, clearance, maintenance dose, loading dose, oral bioavailability [20,801 bytes]
- (hist) 0. Oogenesis and the menstrual cycle [19,964 bytes]
- (hist) Heart failure [19,557 bytes]
- (hist) 7. Distribution of drugs [17,254 bytes]
- (hist) Test characteristics [16,464 bytes]
- (hist) 8. Biotransformation of drugs [16,352 bytes]
- (hist) 38. Antineoplastic drugs: Cytotoxic drugs [16,302 bytes]
- (hist) 39. Antineoplastic drugs: Biological therapy [16,105 bytes]
- (hist) 29. Regulation of gene expression [16,053 bytes]
- (hist) 86. Drug intoxications. Mechanisms, symptoms, treatment [16,031 bytes]
- (hist) 13. Development of the female genital organs. Malformations [16,007 bytes]
- (hist) 11. Formation and derivatives of the heart tube. Partitioning of the cardiac chambers. Malformations [15,654 bytes]
- (hist) 82. Pharmacogenetics, pharmacogenomics. Effects of age, diet and disease on drug action [15,587 bytes]
- (hist) 9. The intestinal tube and its derivatives (with the exception of the pharyngeal gut). Malformations [15,502 bytes]
- (hist) 43. Inflammatory, tumorous diseases as well as disorders associated with hyperplasia of the thyroid gland (+ hyperthyroidism and hypothyroidism) [15,284 bytes]
- (hist) Ovarian cancer [15,210 bytes]
- (hist) 21. RNA metabolism [14,896 bytes]
- (hist) 66. Insulin and oral hypoglycaemic agents. Glucagon [14,820 bytes]
- (hist) 2. Characterisation of agonist-receptor interaction. Occupancy, affinity, dose-response curve, potency, efficacy [14,650 bytes]
- (hist) 25. Water-soluble vitamins [14,609 bytes]
- (hist) 32. Nonneoplastic bone marrow disorders (anaemia, leukocytosis and leukopenia, thrombocytopenia) [14,497 bytes]
- (hist) 84. Drug interactions [14,495 bytes]
- (hist) 3. Neurochemistry of synapses, neurotransmitters, postsynaptic receptors and neuromodulators. EPSP, IPSP [14,313 bytes]
- (hist) 36. Non-steroidal antiinflammatory drugs. Aspirin, paracetamol [14,269 bytes]
- (hist) Breast cancer [14,102 bytes]
- (hist) Cardiac arrest [13,928 bytes]
- (hist) Purpose of investigation [13,853 bytes]
- (hist) 6. Absorption of drugs [13,568 bytes]
- (hist) 5. Development of the blood vessels. Malformations [13,515 bytes]
- (hist) 85. The treatment of the intoxicated patient: decontamination, facilitation of toxicant elimination, antidote administration, supportive treatment [13,457 bytes]
- (hist) 2. Biochemistry of digestion [13,365 bytes]
- (hist) 37. AIDS. Transplantation immunity [13,314 bytes]
- (hist) 24. Protein synthesis 1. Participants and mechanism [13,302 bytes]
- (hist) 9. Excretion of drugs [13,236 bytes]
- (hist) Acute abdomen [13,133 bytes]
- (hist) 41. Principles and evaluation of respiratory function tests. Characteristics and parameters of abnormal breathing mechanics [13,127 bytes]
- (hist) 56. Congenital heart diseases [12,790 bytes]
- (hist) Obesity [12,740 bytes]
- (hist) 4. Mechanisms of drug antagonisms [12,709 bytes]
- (hist) 50. Antidepressants [12,672 bytes]
- (hist) Testicular cancer [12,570 bytes]
- (hist) Enzymes and regulation [12,536 bytes]
- (hist) 25. Protein synthesis 2. Regulation, posttranslational modifications [12,534 bytes]
- (hist) 83. Harmful effects of drugs [12,511 bytes]
- (hist) 21. Regulation of H+ ion concentration in the blood [12,388 bytes]
- (hist) 58. Cysts and tumours of the ovaries (surface epithelial, germ cell, sex cordstromal tumours, tumours, metastases) [12,337 bytes]
- (hist) 18. Describe the two pathways involved in the initiation of blood coagulation [12,330 bytes]
- (hist) 6. Development of the face, formation of the nasal and oral cavities. Malformations [12,325 bytes]
- (hist) 47. Antianxiety and hypnotic drugs [12,184 bytes]